We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

93 hedge funds and large institutions have $404M invested in Lyell Immunopharma in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

586% more call options, than puts

Call options by funds: $48K | Put options by funds: $7K

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0.07% more ownership

Funds ownership: 2.27% → 2.34% (+0.07%)

0% more funds holding

Funds holding: 93 → 93 (0)

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

51% less capital invested

Capital invested by funds: $823M → $404M (-$419M)

Holders
93
Holders Change
–
Holders Change %
0%
% of All Funds
1.49%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
15
Increased
33
Reduced
18
Closed
14
Calls
$48K
Puts
$7K
Net Calls
+$41K
Net Calls Change
+$26K

Top Buyers

1
State Street
State Street
Massachusetts
+$16.7M
2
Goldman Sachs
Goldman Sachs
New York
+$4.11M
3
BlackRock
BlackRock
New York
+$2.19M
4
Bank of America
Bank of America
North Carolina
+$1.95M
5
UBS Group
UBS Group
Switzerland
+$1.94M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.61M
3
Invesco
Invesco
Georgia
-$1.27M
4
KHCM
Kettle Hill Capital Management
New York
-$1.16M
5
Morgan Stanley
Morgan Stanley
New York
-$974K
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
76
Metropolitan Life Insurance Company (MetLife)
New York
$37.3K – – –
Two Sigma Advisers
77
Two Sigma Advisers
New York
$36.8K +$52.6K +530 New
Mariner
78
Mariner
Kansas
$35K +$50.6K +509 New
Lazard Asset Management
79
Lazard Asset Management
New York
$28K – – –
Osaic Holdings
80
Osaic Holdings
Arizona
$27K +$38K +383 +3,192%
ACM
81
Aquatic Capital Management
Illinois
$27K +$38.7K +390 New
SO
82
STRS Ohio
Ohio
$18K – – –
Amundi
83
Amundi
France
$13.7K +$21K +211 New
TRCT
84
Tower Research Capital (TRC)
New York
$10K -$27.3K -275 -64%
CUAMC
85
China Universal Asset Management Company
China
$8.79K +$1.09K +11 +9%
Allspring Global Investments
86
Allspring Global Investments
North Carolina
$5.47K -$69.4K -699 -90%
SBL
87
Sargent Bickham Lagudis
Colorado
$3.47K +$4.97K +50 New
Daiwa Securities Group
88
Daiwa Securities Group
Japan
$3K – – –
US Bancorp
89
US Bancorp
Minnesota
$2.6K +$3.67K +37 New
Dimensional Fund Advisors
90
Dimensional Fund Advisors
Texas
$467 +$76.1K +766 +13%
CS
91
Comerica Securities
Michigan
$156 +$199 +2 New
CS
92
Credit Suisse
Switzerland
$24 -$4.97K -50 Closed
SIC
93
SJS Investment Consulting
Ohio
$3 – – –
KHCM
94
Kettle Hill Capital Management
New York
– -$1.16M -7,920 Closed
Renaissance Technologies
95
Renaissance Technologies
New York
– -$298K -2,035 Closed
Balyasny Asset Management
96
Balyasny Asset Management
Illinois
– -$245K -1,675 Closed
CSS
97
Cubist Systematic Strategies
Connecticut
– -$221K -1,506 Closed
C
98
Certuity
Florida
– -$110K -750 Closed
SEI Investments
99
SEI Investments
Pennsylvania
– -$108K -735 Closed
QT
100
Quantamental Technologies
New York
– -$95K -646 Closed
1 2 3
4
5

LYEL Hedge Fund Activity: Q4 2022 in Review

93 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2022, worth a combined $404M — down 51% from $823M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LYEL positions and 14 closed out — a net gain of 1 holder — while 33 added to existing stakes and 18 trimmed.

The largest buyer was State Street, adding an estimated $16.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.1M.

  • 93 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $404M of Lyell Immunopharma stock for Q4 2022, down 51% quarter-over-quarter.
  • 15 funds opened new Lyell Immunopharma positions in Q4 2022 and 14 closed out, a net change of +1 holder.
  • The largest Lyell Immunopharma buyer in Q4 2022 was State Street, an estimated $16.7M added.
  • The largest Lyell Immunopharma seller in Q4 2022 was T. Rowe Price Associates, an estimated $8.1M sold.

Based on aggregated 13F filings for Q4 2022.